Morphic Therapeutic (MORF) Event May 12, 2022, 12:46 UTC 13 1 comments (80% Positive) Morphic Holding, Inc. (MORF) Provides Update on grows for its mission to create integrin medicines Comment Full text
MeiraGTx Holding (MGTX) Event May 12, 2022, 12:11 UTC 11 1 comments (85% Positive) MeiraGTx Holdings plc (MGTX) Reports Q2 2022 Financial Results Comment Full text
Pacira BioSciences Inc (PCRX) Event May 12, 2022, 12:09 UTC 11 1 comments (10% Negative) PACIRA BIOSCIENCES, INC. (PCRX) Announces Delay in million Trials for managing osteoarthritis Due to Pandemic-Related Challenges, Manufacturing Considerations, Safety Review, Efficacy Assessment Comment Full text
Evelo Biosciences, Inc. (EVLO) Event May 12, 2022, 12:06 UTC 11 1 comments (10% Negative) Evelo Biosciences, Inc. (EVLO) Reports Q2 2022 Financial Results Comment Full text
Akouos Inc (the company became a subdivision of the company LIlly (LLY)) (AKUS) Event May 12, 2022, 11:45 UTC 11 1 comments (10% Negative) Akouos, Inc. (AKUS) Reports Q2 2022 Financial Results Comment Full text
Applied Therapeutics (APLT) Event May 12, 2022, 11:11 UTC 11 1 comments (30% Negative) APPLIED THERAPEUTICS, INC. (APLT) Reports Q2 2022 Financial Results Comment Full text
Altimmune Inc (ALT) Event May 12, 2022, 11:07 UTC 11 1 comments (10% Negative) ALTIMMUNE, INC. (ALT) Reports Q2 2022 Financial Results Comment Full text
Cabaletta Bio Inc (CABA) Event May 12, 2022, 11:07 UTC 12 1 comments (90% Positive) CABALETTA BIO, INC. (CABA) Announces Enrollment Update for results Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment Comment Full text
Tcr2 Therapeutics Inc (the company was acquired by Adaptimmune Therapeutics plc (NASDAQ: ADAP)) (TCRR) Event May 12, 2022, 11:02 UTC 10 1 comments (70% Positive) TCR2 THERAPEUTICS INC. (TCRR) Reports Q2 2022 Financial Results Comment Full text
OptiNose Inc (OPTN) Event May 12, 2022, 11:00 UTC 11 1 comments (30% Negative) OPTINOSE, INC. (OPTN) Reports Q2 2022 Financial Results Comment Full text